$HNGE

Pursley James sold $2.3M of HNGE

Pursley James (President) sold 33,000 shares of Hinge Health, Inc. (HNGE) at an average of $69.31 ($68.93–$70.89, $2.29M total) across 3 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pursley James
Published Jun 23, 2026, 8:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HNGE
Neutral
medium confidence
Mentioned
$HNGE
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may marginally influence sentiment, but it does not change company fundamentals in the text provided.

02

Market read

A scheduled insider sale of ~$2.29M worth of HNGE shares was filed, offering limited incremental trading signal.

03

What to watch

Traders may want to compare with prior insider activity cadence and whether other executives also sell around the same window.

Relevance 5/10Novelty 4/10Timing: after-hours/filing update (SEC Form 4 filed 2026-06-23)

Background

The article is an SEC Form 4 insider transaction disclosure for Hinge Health, Inc.

Company-level read

Ticker impact

$HNGENeutralMedium confidence
Context

Form 4 shows President Pursley James sold 33,000 HNGE shares in open-market trades under a 10b5-1 plan on 2026-06-22.

Expected impact

Likely minimal price impact; any effect is short-lived unless follow-on insider selling appears.

Evidence & confidence

The filing is a disclosed insider transaction with pre-arranged 10b5-1 structure; it is not a new operational or financial catalyst.

Market effects

No sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish fundamentals.

Key entities

  • Hinge Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Pursley James

    President and reporting insider who sold shares.

  • 10b5-1 plan

    Pre-arranged plan cited as the basis for the sale.

Related articles

$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.